Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 23, 2022
Data Byte

Translational spotlight on East-West innovation 

Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities
BioCentury | Jul 30, 2021
Distillery Therapeutics

GHRH agonist to protect retinal ganglion cells from optic neuropathy

DISEASE CATEGORY: Ophthalmic
INDICATION: Optic neuropathy A team from the Chinese University of Hong Kong showed a GHRH receptor agonist could protect retinal ganglion cells from optic
BioCentury | Feb 11, 2019
Distillery Therapeutics

Cancer

BioCentury | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

BioCentury | Jan 25, 2017
Distillery Therapeutics

Cancer

BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

BioCentury | Nov 2, 2015
Company News

Biscayne Pharmaceuticals, Insero Health deal

BioCentury | Sep 8, 2014
Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne's GHRH antagonist for cancer could be first in class
BioCentury | Jun 9, 2014
Company News

Inovio, Plumbline Life Sciences Inc. deal

Items per page:
1 - 10 of 70